Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
August 08, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
June 18, 2024 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases,...
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024 11:15 ET
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
March 19, 2024 02:00 ET
|
AstriVax
Dr. Fanning brings a wealth of experience in creating infectious disease pipelines by internal R&D and licensing As the CBO of AstriVax, he will lead the company’s business development, including...
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
January 05, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine
December 12, 2023 01:00 ET
|
AstriVax
The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO).The grant will be used to accelerate the development of the company’s therapeutic vaccine targeting chronic...
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
October 11, 2023 08:00 ET
|
Assembly Biosciences, Inc.
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 ...
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 19, 2023 16:05 ET
|
Assembly Biosciences, Inc.
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist...